Alzheimer's Drugs May Work in Whole New Way, Study Finds

THURSDAY, Sept. 11, 2024 -- Two monoclonal antibody treatments to slow Alzheimer's disease, lecanemab (Leqembi) and donanemab (Kisunla), have been approved by the U.S. Food and Drug Administration over the past two years.

It's thought the drugs...